引用本文
  • 李苏华,邓华瑜*,陈黎.细胞外调节蛋白激酶在雌激素促乳腺癌细胞MCF-7增殖中的作用[J].第二军医大学学报,2009,30(4):395-399    [点击复制]
  • LI Su-hua,DENG Hua-yu*,CHEN Li.Role of extracellular signal-regulated protein kinase in estrogen-induced proliferation of breast cancer cell line MCF-7[J].Acad J Sec Mil Med Univ,2009,30(4):395-399   [点击复制]
【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2927次   下载 2511 本文二维码信息
码上扫一扫!
细胞外调节蛋白激酶在雌激素促乳腺癌细胞MCF-7增殖中的作用
李苏华,邓华瑜*,陈黎
0
(重庆医科大学病理生理学教研室,重庆 400016)
摘要:
目的:探讨细胞外调节蛋白激酶(ERK)在雌激素促乳腺癌细胞MCF-7增殖、细胞周期转化中的作用及机制。方法:以雌激素受体阳性乳腺癌细胞MCF-7为研究对象, MTT法检测17β-雌二醇(17β-E2)对MCF细胞增殖的影响,确定实验处理用浓度;MTT法检测PD98059对17β-E2促MCF-7细胞增殖作用的影响,求取其中效抑制浓度;流式细胞术检测细胞周期;TRAP-PCR银染法检测端粒酶活性,Western印迹法检测p-ERK1/2、野生型p53蛋白水平;RT-PCR检测野生型p53 mRNA水平。结果:ERK磷酸化抑制剂PD98059能抑制17β-E2对MCF-7细胞的促增殖作用,具有时效-量效关系,其差异具有显著统计学意义(P<0.01), 各作用时间点PD98059中效抑制浓度分别为89.28 μmol/L·24 h、39.81 μmol/L·48 h、21.87 μmol/L·72 h。应用PD98059 48 h后,能抑制17β-E2促进MCF-7细胞周期转化作用,使G1期细胞增加,S期和G2期细胞减少(P<0.01); 阻抑17β-E2增强MCF-7细胞端粒酶活性的作用(P<0.05); 增强野生型p53蛋白表达和p53基因转录水平(P<0.01);p-ERK1/2蛋白表达水平显著降低(P<0.01)。 结论:ERK在17β-E2促乳腺癌细胞MCF-7增殖、细胞周期转化中具有重要的作用,其机制与野生型p53转录和端粒酶活性改变有关。
关键词:  17β-雌二醇  PD98059  细胞外调节蛋白激酶  p53基因  端粒酶  乳腺肿瘤
DOI:10.3724/SP.J.1008.2009.0395
投稿时间:2008-07-23修订日期:2008-09-27
基金项目:
Role of extracellular signal-regulated protein kinase in estrogen-induced proliferation of breast cancer cell line MCF-7
LI Su-hua,DENG Hua-yu*,CHEN Li
(Department of Pathophysiology, Chongqing Medical University,Chongqing 400016,China)
Abstract:
Objective:To investigate the role of extracellular signal-regulated protein kinase (ERK) in estrogen-induced proliferation and cell cycle transformation of breast cancer cell line MCF-7 and the related mechanisms. Methods: Estrogen receptor-positive breast cancer cell line MCF-7 was used in our study. The effects of 17β-E2 on the proliferation of MCF-7 cells was investigated by MTT assay to determine the optimal concentration of 17β-E2 for the following experiment. The effect of PD98059 on 17β-E2-induced proliferation of MCF-7 cells was measured by MTT assay to determine the intermediate concentration of PD98059. The cell cycle was analyzed by flow cytometry and telomerase activity was determined by Telomerase repeat amplification protocol PCR (TRAP-PCR) silver staining. The expression of wild-type p53 and phosphorylated ERK1/2 protein was determined by Western blotting and the expression of wild-type p53 mRNA was detected by RT-PCR. Results: ERK phosphorylation inhibitor PD98059 inhibited the proliferation of MCF-7 cells treated with 17β-E2 in a time- and dose-dependent manner(P<0.01). The intermediate concentrations of PD98059 were 89.28 μmol/L for 24 h,39.81 μmol/L for 48 h and 21.87 μmol/L for 72 h. Treatment with 20 μmol/L PD98059 for 48 h reversed the promoting effect of 17β-estradiol on the cell cycle transformation of MCF-7, increasing the number of G1 phase cells and decreasing the number of S and M phase cells(P<0.01),inhibited the enhancing effect of 17β-E2 on the telomerase activity of MCF-7 cells(P<0.05), increased the protein expression level and genetic transcription of wild-type p53 (P<0.01),and decreased the expression of p-ERK1/2 protein(P<0.01).Conclusion: ERK plays an important role in 17β-E2-induced proliferation and cell cycle transformation of breast cancer cell line MCF-7, which might be related to the changes of genetic transcription of wild-type p53 and telomerase activity.
Key words:  17beta-estradiol  PD98059  extracellular regulated protein kinase  p53 gene  telomerase  breast neoplasms